Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Cash (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Change in Cash for 9 consecutive years, with -$68.6 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Cash rose 20.7% year-over-year to -$68.6 million; the TTM value through Mar 2026 reached -$233.4 million, down 169.48%, while the annual FY2025 figure was -$251.4 million, 171.18% down from the prior year.
  • Change in Cash hit -$68.6 million in Q1 2026 for Bicycle Therapeutics, down from -$20.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $504.4 million in Q2 2024 and bottomed at -$86.5 million in Q1 2025.
  • Average Change in Cash over 5 years is $7.1 million, with a median of -$34.6 million recorded in 2022.
  • Year-over-year, Change in Cash tumbled 1319.67% in 2022 and then skyrocketed 2154.88% in 2023.
  • Bicycle Therapeutics' Change in Cash stood at -$22.3 million in 2022, then tumbled by 104.63% to -$45.7 million in 2023, then soared by 75.16% to -$11.3 million in 2024, then crashed by 77.72% to -$20.2 million in 2025, then crashed by 240.51% to -$68.6 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$68.6 million, -$20.2 million, and -$73.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.